Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.
Models of immunity to malaria indicate the importance of CD8+ T cell responses for targeting intrahepatic stages and antibodies for targeting sporozoite and blood stages. We designed a multistage adenovirus 5 (Ad5)-vectored Plasmodium falciparum malaria vaccine, aiming to induce both types of respon...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3189181?pdf=render |
id |
doaj-9c9a093b9e1d42e4bfd2af438749573f |
---|---|
record_format |
Article |
spelling |
doaj-9c9a093b9e1d42e4bfd2af438749573f2020-11-24T22:21:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01610e2458610.1371/journal.pone.0024586Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.Martha SedegahCindy TammingaShannon McGrathBrent HouseHarini GaneshanJennylynn LejanoEsteban AbotGlenna J BananiaRenato SayoFouzia FarooqMaria BelmonteNalini ManoharNancy O RichieChloe WoodCarole A LongDavid RegisFrancis T WilliamsMeng ShiIlin ChuangMichele SpringJudith E EpsteinJose Mendoza-SilveirasKeith LimbachNoelle B PattersonJoseph T BruderDenise L DoolanC Richter KingLorraine SoissonCarter DiggsDaniel CarucciSheetij DuttaMichael R HollingdaleChristian F OckenhouseThomas L RichieModels of immunity to malaria indicate the importance of CD8+ T cell responses for targeting intrahepatic stages and antibodies for targeting sporozoite and blood stages. We designed a multistage adenovirus 5 (Ad5)-vectored Plasmodium falciparum malaria vaccine, aiming to induce both types of responses in humans, that was tested for safety and immunogenicity in a Phase 1 dose escalation trial in Ad5-seronegative volunteers.The NMRC-M3V-Ad-PfCA vaccine combines two adenovectors encoding circumsporozoite protein (CSP) and apical membrane antigen-1 (AMA1). Group 1 (n = 6) healthy volunteers received one intramuscular injection of 2×10∧10 particle units (1×10∧10 each construct) and Group 2 (n = 6) a five-fold higher dose. Transient, mild to moderate adverse events were more pronounced with the higher dose. ELISpot responses to CSP and AMA1 peaked at 1 month, were higher in the low dose (geomean CSP = 422, AMA1 = 862 spot forming cells/million) than in the high dose (CSP = 154, p = 0.049, AMA1 = 423, p = 0.045) group and were still positive at 12 months in a number of volunteers. ELISpot depletion assays identified dependence on CD4+ or on both CD4+ and CD8+ T cells, with few responses dependent only on CD8+ T cells. Intracellular cytokine staining detected stronger CD8+ than CD4+ T cell IFN-γ responses (CSP p = 0.0001, AMA1 p = 0.003), but similar frequencies of multifunctional CD4+ and CD8+ T cells secreting two or more of IFN-γ, TNF-α or IL-2. Median fluorescence intensities were 7-10 fold higher in triple than single secreting cells. Antibody responses were low but trended higher in the high dose group and did not inhibit growth of cultured P. falciparum blood stage parasites.As found in other trials, adenovectored vaccines appeared safe and well-tolerated at doses up to 1×10∧11 particle units. This is the first demonstration in humans of a malaria vaccine eliciting strong CD8+ T cell IFN-γ responses.ClinicalTrials.govNCT00392015.http://europepmc.org/articles/PMC3189181?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Martha Sedegah Cindy Tamminga Shannon McGrath Brent House Harini Ganeshan Jennylynn Lejano Esteban Abot Glenna J Banania Renato Sayo Fouzia Farooq Maria Belmonte Nalini Manohar Nancy O Richie Chloe Wood Carole A Long David Regis Francis T Williams Meng Shi Ilin Chuang Michele Spring Judith E Epstein Jose Mendoza-Silveiras Keith Limbach Noelle B Patterson Joseph T Bruder Denise L Doolan C Richter King Lorraine Soisson Carter Diggs Daniel Carucci Sheetij Dutta Michael R Hollingdale Christian F Ockenhouse Thomas L Richie |
spellingShingle |
Martha Sedegah Cindy Tamminga Shannon McGrath Brent House Harini Ganeshan Jennylynn Lejano Esteban Abot Glenna J Banania Renato Sayo Fouzia Farooq Maria Belmonte Nalini Manohar Nancy O Richie Chloe Wood Carole A Long David Regis Francis T Williams Meng Shi Ilin Chuang Michele Spring Judith E Epstein Jose Mendoza-Silveiras Keith Limbach Noelle B Patterson Joseph T Bruder Denise L Doolan C Richter King Lorraine Soisson Carter Diggs Daniel Carucci Sheetij Dutta Michael R Hollingdale Christian F Ockenhouse Thomas L Richie Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS ONE |
author_facet |
Martha Sedegah Cindy Tamminga Shannon McGrath Brent House Harini Ganeshan Jennylynn Lejano Esteban Abot Glenna J Banania Renato Sayo Fouzia Farooq Maria Belmonte Nalini Manohar Nancy O Richie Chloe Wood Carole A Long David Regis Francis T Williams Meng Shi Ilin Chuang Michele Spring Judith E Epstein Jose Mendoza-Silveiras Keith Limbach Noelle B Patterson Joseph T Bruder Denise L Doolan C Richter King Lorraine Soisson Carter Diggs Daniel Carucci Sheetij Dutta Michael R Hollingdale Christian F Ockenhouse Thomas L Richie |
author_sort |
Martha Sedegah |
title |
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. |
title_short |
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. |
title_full |
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. |
title_fullStr |
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. |
title_full_unstemmed |
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. |
title_sort |
adenovirus 5-vectored p. falciparum vaccine expressing csp and ama1. part a: safety and immunogenicity in seronegative adults. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-01-01 |
description |
Models of immunity to malaria indicate the importance of CD8+ T cell responses for targeting intrahepatic stages and antibodies for targeting sporozoite and blood stages. We designed a multistage adenovirus 5 (Ad5)-vectored Plasmodium falciparum malaria vaccine, aiming to induce both types of responses in humans, that was tested for safety and immunogenicity in a Phase 1 dose escalation trial in Ad5-seronegative volunteers.The NMRC-M3V-Ad-PfCA vaccine combines two adenovectors encoding circumsporozoite protein (CSP) and apical membrane antigen-1 (AMA1). Group 1 (n = 6) healthy volunteers received one intramuscular injection of 2×10∧10 particle units (1×10∧10 each construct) and Group 2 (n = 6) a five-fold higher dose. Transient, mild to moderate adverse events were more pronounced with the higher dose. ELISpot responses to CSP and AMA1 peaked at 1 month, were higher in the low dose (geomean CSP = 422, AMA1 = 862 spot forming cells/million) than in the high dose (CSP = 154, p = 0.049, AMA1 = 423, p = 0.045) group and were still positive at 12 months in a number of volunteers. ELISpot depletion assays identified dependence on CD4+ or on both CD4+ and CD8+ T cells, with few responses dependent only on CD8+ T cells. Intracellular cytokine staining detected stronger CD8+ than CD4+ T cell IFN-γ responses (CSP p = 0.0001, AMA1 p = 0.003), but similar frequencies of multifunctional CD4+ and CD8+ T cells secreting two or more of IFN-γ, TNF-α or IL-2. Median fluorescence intensities were 7-10 fold higher in triple than single secreting cells. Antibody responses were low but trended higher in the high dose group and did not inhibit growth of cultured P. falciparum blood stage parasites.As found in other trials, adenovectored vaccines appeared safe and well-tolerated at doses up to 1×10∧11 particle units. This is the first demonstration in humans of a malaria vaccine eliciting strong CD8+ T cell IFN-γ responses.ClinicalTrials.govNCT00392015. |
url |
http://europepmc.org/articles/PMC3189181?pdf=render |
work_keys_str_mv |
AT marthasedegah adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT cindytamminga adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT shannonmcgrath adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT brenthouse adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT hariniganeshan adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT jennylynnlejano adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT estebanabot adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT glennajbanania adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT renatosayo adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT fouziafarooq adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT mariabelmonte adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT nalinimanohar adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT nancyorichie adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT chloewood adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT carolealong adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT davidregis adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT francistwilliams adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT mengshi adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT ilinchuang adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT michelespring adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT juditheepstein adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT josemendozasilveiras adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT keithlimbach adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT noellebpatterson adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT josephtbruder adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT deniseldoolan adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT crichterking adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT lorrainesoisson adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT carterdiggs adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT danielcarucci adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT sheetijdutta adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT michaelrhollingdale adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT christianfockenhouse adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults AT thomaslrichie adenovirus5vectoredpfalciparumvaccineexpressingcspandama1partasafetyandimmunogenicityinseronegativeadults |
_version_ |
1725770731361402880 |